SPN-817
817P210
Phase 2 small_molecule active
Quick answer
SPN-817 for Focal Onset Seizures is a Phase 2 program (small_molecule) at SUPERNUS PHARMACEUTICALS, INC. with 2 ClinicalTrials.gov record(s).
Program details
- Company
- SUPERNUS PHARMACEUTICALS, INC.
- Indication
- Focal Onset Seizures
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active